Orifarm got Covid-19 discount on Takeda purchases: "The timing was in our favor"

When Orifarm bought products worth DKK 4.6bn from Japanese Takeda in spring 2020, it got a solid coronavirus discount due to turbulent times. "The timing was in our favor," says Orifarm CEO Erik Sandberg.

Photo: Orifarm / PR

When pharmaceutical supplier Orifarm bought a wide range of products from Japanese Takeda for DKK 4.6bn (USD 726.0m) in March 2020, the company was – in the words of CEO Erik Sandberg – "in the eye of the hurricane". At that time, Covid-19 was on everybody's lips and there was a vast amount of uncertainty. The uncertainty, however, led to the purchase casting off a significant "pandemic discount", says Sandberg, according to Danish newspaper Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs